Based on the reported assay of immunogenic cell death and T-cell activation, a DNA topoisomerase II inhibitor was proposed to induce the protein HMGB1 release and IFN-I expression in tumor; subsequently, DCs were activated through both NFκB activation and the STING-dependent IFN-I pathway, and then T cells were recruited into the tumor to increase therapeutic efficacy (Wang et al., 2019). Here, HMGB1 is linked to neoplasm.